Zacks Investment Research
29 Oct 2026, 15:50 UTC · 2h ago
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
Impact · against what's priced in
The article provides a preview of Zimmer Biomet's Q3 earnings, highlighting modest revenue growth and a slight EPS decline. Since these consensus estimates and the history of earnings beats are already public knowledge, the report contains no immediate catalysts for the stock price.
- ZBH+0.00
No priced-in read yet
- In context
The company is expected to report Q3 revenue of $2.05 billion (up 2.2%) and EPS of $1.89 (down 0.5%). These figures represent baseline consensus estimates and do not introduce new catalysts beyond the scheduled earnings date.
Read from the article alone
Top 1 mover · tap to explore
